<document xmlns:xlink="http://www.w3.org/1999/xlink" xmlns:z="http://www.ebi.ac.uk/z" source="Whatizit"><text><SENT sid="0" pm="."><plain><z:e sem="disease" ids="C0033845" disease_type="Disease or Syndrome" abbrv="">Pseudotumor cerebri</z:e> (PTC) is an uncommon disorder in the pediatric population </plain></SENT>
<SENT sid="1" pm="."><plain>It is not a benign condition </plain></SENT>
<SENT sid="2" pm="."><plain>It can cause permanent <z:e sem="disease" ids="C0456909" disease_type="Disease or Syndrome" abbrv="">vision loss</z:e> </plain></SENT>
<SENT sid="3" pm="."><plain>The most recently recognized risk factor for this disorder is recombinant human growth hormone (GH) therapy </plain></SENT>
<SENT sid="4" pm="."><plain>Data from Genentech's National Cooperative Growth Study (NCGS), a postmarketing surveillance program, are analyzed to examine the relationship between GH therapy and PTC </plain></SENT>
<SENT sid="5" pm="."><plain>Several areas are addressed, including plausibility, probability, clinical and laboratory presentations, management, clinical outcome, present state of knowledge, and future recommendations </plain></SENT>
</text></document>